Activating mutations in the EGFR gene were first identified in non-small cell lung cancers (NSCLC) in 2004, marking one of the most significant advancements in understanding the molecular biology of these tumors [52]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.